Expert review of clinical pharmacologyHumansJanus Kinase InhibitorsDrug MonitoringDose-Response RelationshipDrug
Therapeutic drug monitoring of Janus kinase inhibitors for precision dosing: where do we stand ?
Jérémie Tachet, Catia Marzolini, Laurent A Decosterd, Monia Guidi, François R Girardin
Published: 202510.1080/17512433.2025.2576698
Abstract
INTRODUCTION: Janus kinase inhibitors (JAKIs) emerged as novel therapies for a wide range of autoimmune and myeloproliferative neoplasms. JAKIs have remarkable clinical effectiveness, but emerging safety concerns have sparked interest in precision do…
Preview only. Read the full abstract at the source